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Christine N. Duncan, Lynda Vrooman, Erin M. Apfelbaum, Katherine Whitley,
Lori Bechard, Leslie E. LehmannChildren may be at increased risk for vitamin D deficiency following HSCT because of lack of sun exposure,
the recommended use of sunscreen, dietary insufficiency, malabsorption, and the use of certain medications.
We prospectively assessed the prevalence of and risk factors for 25-hydroxy (25-OH) vitamin D deficiency in
67 patients transplanted at our institution. 25-OH vitamin D levels were checked during 3 separate 4-week
periods in the spring, autumn, and winter. Subjects were\2 years following transplant and/or being treated
for chronic graft-versus-host disease (cGVHD). Levels less than 20 ng/mL were considered deficient, and
those less than 30 ng/mL were considered insufficient. The mean 25-OH vitamin D level was 22.8 ng/mL
(range: 7-46.2). A total of 80.6% (confidence interval [CI] 69.1%-89.3%) of patients had a level less than
the lower limit of the institutional normal range. The deficiency rate was 37.3% (CI 25.8%-50%). The
mean parathyroid hormone (PTH) level was 77.5 (SD 5 80.5). There was no correlation between 25-OH
vitamin D and PTH levels. We evaluated potential risk factors for 25-OH vitamin D deficiency including
age, season of testing, sun exposure, sunscreen use, use of steroid or calcineurin inhibitor, race, and dairy
intake. In multivariate logistic regression, only older age was found to be a risk factor for deficiency
(P 5 .004). Patients with deficient levels were treated with 50,000 IU of ergocalciferol once weekly for 6
weeks. A postrepletion 25-OH level was available for 22 patients. The majority of repleted patients had
a normal posttreatment level (63.6%). The postsupplementation level corrected into the insufficient range
for 31.8% of patients and 4.6% remained deficient. Vitamin D insufficiency and deficiency are common fol-
lowing HSCT. Further investigation into potential risk factors and the appropriate supplementation for these
patients is warranted.
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Vitamin D deficiency is a recognized international
health issue [1-11]. An adequate supply of vitamin D is
needed for skeletal development, and vitamin D
deficiency in childhood can interfere with optimal
skeletal calcium deposition [12]. Emerging evidence
suggests that vitaminDmayplay a role in immunomodu-
lation, decreasing the risk for certain cancers, and the pre-
vention ofmultiple chronic illnesses [11,13-29].Children
are potentially at increased risk for vitamin D deficiencyiatric Oncology, Dana-Farber Cancer Institute, Boston,
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for multiple reasons. Vitamin D is typically acquired
from exposure to sunlight and from dietary sources
[11,30]. Following HSCT, children may have decreased
exposure to direct sunlight because of hospitalization
and convalescence. Additionally, properly applied sun-
screen may reduce vitamin D3 synthesis by 99% [31].
Sunscreen use is commonly recommended posttrans-
plant and, when used as directed, may place patients at
greater risk for vitamin D deficiency. Other potentially
contributing factors to post-HSCT vitaminD deficiency
are decreased bioavailability because of malabsorption,
obesity resulting in sequestration of vitamin D in fat,
and increased catabolism because of glucocorticoid and
calcineurin inhibitor use [11,32,33].
The recommended daily vitamin D intake for
healthy children and adolescents is 400 IU [34]. There
are many published regimens for the treatment of
vitamin D deficiency. Most repletion strategies involve
weekly enteral supplementation with high-dose
vitamin D, although intramuscular injection and
ultraviolet exposure have also been recommended749
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supplementation for children following HSCT is
unknown. This prospective study investigated the
prevalence of 25-hydroxy (25-OH) vitamin D
deficiency in children and adolescents following
HSCT. We evaluated potential risk factors for 25-
OH vitamin D deficiency and the efficacy of a weekly
oral repletion strategy.MATERIALS AND METHODS
We prospectively measured the 25-OH vitamin D
and parathyroid hormone (PTH) levels of post-HSCT
patients during 3 separate 4-week periods in the spring
and autumn of 2009 and in winter 2010. Patients aged
1 to 21 years were eligible for participation if they were
transplanted at our institution and were within 2 years
of stem cell infusion at the time of enrollment. Patients
who were\2 years from HSCT were eligible for par-
ticipation if they were receiving immunosuppression
for the treatment of chronic graft-versus-host disease
(GVHD). We evaluated patients\2 years from trans-
plant and those with chronic GVHD (cGVHD) in an
effort to exclude patients less medically impacted by
HSCT. Exclusion criteria included having a vitamin
D level checked within 6 months of enrollment, as it
is the standard at our institution to check no more
frequently than every 6 months unless clinically indi-
cated, known vitamin D wasting condition, vitamin
D supplementation at enrollment, and the inability
to receive enteral vitamin D repletion. 25-OH vitamin
D levels$30 ng/mLwere considered normal, levels 20
to 29 ng/mL were considered insufficient, and levels
\20 were considered deficient. Patients who had
a 25-OH vitamin D level in the deficient range were
given repletion with enteral ergocalciferol at the dose
of 50,000 IU once weekly for 6 weeks. A follow-up
level was checked within 4 weeks of the completion
of repletion. A PTH level was checked at the time of
the initial 25-OHVitaminD level. It was not evaluated
following repletion. The institutional normal range
for PTH is 10-65 pg/mL.
Demographic information, baseline transplant, and
the list of medications prescribed at enrollment were
abstracted from the medical record. Demographic
data included sex, age at enrollment, and race
(Caucasian, African-American, Hispanic, Asian, and
mixed ethnicity). Baseline transplant data included the
type of transplant, the donor source (unrelated or
related), the stem cell source, time from transplant,
and the indication for transplantation. A survey admin-
istered at the time of enrollment assessed potential risk
factors for vitamin D deficiency. Subjects were queried
about their intake of vitamin D–containing nutrition or
supplements using 24-hour dietary recall. This in-
cluded the use of parenteral nutrition, the volume of
daily consumption of milk (cow and soy) and formula,and the use of any nutritional supplements. Daily expo-
sure to direct sunlight was categorized as\30 minutes
per day, between 30 minutes and 1 hour per day, 1 to 2
hours per day, and .2 hours per day. Subjects were
asked to categorize their use of sunscreen as almost al-
ways/rarely go outside without it; sometimes/used
when planning to be outside for more than 1 hour; or
rarely/less than once per week.
Statistical Methods
The prevalence’s were calculated and presented
with 95% exact confidence intervals for binomial
parameters. Potential risk factors were evaluated using
a multivariate logistic regression. Sun exposure was
assessed with the 4-point scale and sunscreen use
with the 3-point scale described in the previous sec-
tion. Dietary intake of vitamin D–containing bever-
ages or supplements was evaluated with a 24-hour
dietary recall and was analyzed as a continuous vari-
able. The type of transplant, sex of patient, the absence
or presence of active GVHD, and calcineurin inhibitor
and steroid use were analyzed as binary variables. The
indication for transplantation was analyzed as the cat-
egoric variables hematologic malignancy, solid tumor,
and nonmalignant condition. Age was analyzed as
a continuous variable. The underlying disease was
treated as a categoric variable.
To describe the effect of ergocalciferol supple-
mentation once weekly, we report the mean levels
with standard deviations (SD) prior to and following
treatment. Patients who were prescribed ergocalciferol
for repletion, but died before completing the period of
repletion, were included in the analysis of prevalence
and excluded from analysis of the effect of ergocalci-
ferol supplementation. The mean change in vitamin
D levels after supplementation was evaluated using
the Wilcoxan signed rank test. The Pearson correla-
tion coefficient was used to assess the linear correlation
between vitamin D and PTH levels.RESULTS
Between May 21, 2009, and February 23, 2010,
a total of 67 patients had a 25-OH vitamin D level col-
lected. The seasonal distribution of testing was 41.8%
in the spring, 23.9% in the autumn, and 34.3% in the
winter. The population was 62.7%male and had a me-
dian age at enrollment of 73 months (mean 5 94.6
months). The racial composition of the study popula-
tion was 64.2% Caucasian, 13.4% Hispanic, 11.9%
Asian, 7.5% African American, and 3% mixed ethnic-
ity (Table 1). The majority of patients, 82.1%, had an
allogeneic HSCT (70.9% unrelated donor). The me-
dian duration of time since HSCT was 69 days
(mean5 133 days). Themajority of patients took a cal-
cineurin inhibitor (68.7%) and/or corticosteroids
(38.8%), and 10.4% of the patients had active
Table 1. Patient Characteristics and Potential Risk Factors
Normal
(>30 ng/mL)
Insufficient
(20-29 ng/mL)
Deficient
(<20 ng/mL)
Mean age (months) 84 78 119
Male:female 62:38 55:45 72:28
Underlying malignancy (%) 69 66 60
Allogenic HSCT (%) 77 72 96
Unrelated donor (%) 80 59 78
Mean days from HSCT 46 133 113
cGVHD (%) 4 5 4
 Cutaneous (% of GVHD) 17% 34% 34%
 Oral (% of GVHD) 17% 17% 34%
 Occular (% of GVHD) 0 0 34%
 Pulmonary (% of GVHD) 0 34% 0
Prednisone use (%) 9 15 24
Calcineurin inhibitor use (%) 15 31 38
Mean volume milk/day (oz) 14 10 14
Sunscreen use (%)
Always 31 31 32
Sometimes 54 59 44
Rarely 15 10 24
Daily time outside (%)
<30 minutes 70 61 67
30 minutes-1 hour 15 13 8
1-2 hours 15 13 25
>2 hours 0 13 0
HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-
versus-host disease.
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were not analyzed as a separate cohort because of the
small number of patients with GVHD.
The mean 25-OH vitamin D level was 22.8 ng/mL
(median 5 23, range: 7-42.6). The prevalence of
either vitamin D deficiency or insufficiency was
80.6% (95% confidence interval [CI] 69.1%-89.3%).
The prevalence of vitamin D deficiency was 37.3%
(CI 25.8%-50%) and insufficiency was 43.3% (CI
31.2%-56.0%). The mean 25-OH vitamin D level
was highest in the autumn (28.0 ng/mL) in contrast
to the mean values in the spring (21.0 ng/mL) and
winter (21.4 ng/mL) (P 5 .89). The 25 patients with
25-OH vitamin D levels in the deficient range were
prescribed ergocalciferol and 22 patients completed 6
weeks of repletion. Three patients who were pre-
scribed repletion died of relapsed leukemia prior to
follow-up. The mean change in 25-OH vitamin D
levels following supplementation was 18.8 (SD 5
11.3, range: 8-42). Of the evaluable subjects, 63.6%
had a postsupplementation level in the normal range,
31.8% had levels in the insufficient range, and 4.5%
remained deficient. The mean presupplementation
level in patients with normal postsupplementation
values was 15.1 ng/mL (SD 5 2.7, range: 8.3-19.3)
compared to 11.8 ng/mL (SD 5 4.0, range: 7-17.2)
in subjects who had abnormal postsupplementation
levels (P 5 .0699).
A PTH level at enrollment was available for 63
patients. The mean value was 77.5 pg/mL (SD 5 80.5,
range: 7.2-450). The correlation coefficient between the
vitamin D and PTH levels was 20.0055 (P 5 .9647),and there was not statistical evidence to conclude
a correlation.
In multivariate analysis of the age at enrollment,
the use of sunscreen, daily sun exposure, the daily
milk intake, calcineurin or steroid use, and race, only
older age at enrollment was found to be a risk factor
for vitamin D deficiency (P 5 .004).DISCUSSION
Vitamin D insufficiency and deficiency were com-
mon in this population of children and adolescents
following HSCT in Boston. The mean serum vitamin
D level, 22.8 ng/mL (56.9 nmol/L), in this population
is lower than mean levels reported in the National
Health andNutrition Examination Surveys (NHANES)
2000-2004, which reported mean 25-OH levels of 76.43
nmol/L in children aged 1 to 5 years; 70.02 nmol/L in
children aged 6 to 11 years, and 63.86 nmol/L in adoles-
cents aged 12 to 19 years [41]. The prevalence of defi-
ciency in this study, 37.3%, is higher than the 12.1%
reported in healthy infants and toddlers in Boston and
is similar to a prevalence of 42% reported in healthy ad-
olescents, defined as age.11years, living inBoston [2,3].
However, the deficiency rate in the subset of patients in
our study aged 11 years or older was 66.7%.
Potential risk factors for vitamin D deficiency are
well reported and are inconsistent across studies
[2,3,25,42,43]. We investigated multiple potential risk
factors and only identified older age as a predictor
of vitamin D deficiency. Other studies support an
increased risk of vitamin D deficiency in healthy
adolescents [8,9]. The underlying cause for the
increased risk of deficiency in adolescents and young
adults is unclear. Potential contributors include
greater intake of nonvitamin D–containing beverages
such as soda and juice and less compliance with
recommendations to avoid sun exposure. Higher rates
of GVHD have been reported in adult patients
compared with children [44,45]. We considered the
possibility that the adolescent patients had more
GVHD and thus more deficiency because of
malabsorption and the use of corticosteroid and
calcineurin inhibitors. However, in this sample, the
rates of GVHD and immunosuppression use were
similar between the adolescents and younger children.
The impact of suboptimal vitamin D status on the
bone and overall health of this population is not known.
Cutaneous absorption of solar ultraviolet B
radiation is responsible for the conversion of 7-
dehydrocholesterol to previtamin D3, which is
converted to vitamin D3 [11,30]. People living at
higher latitudes have less exposure to UV light
during the winter, and seasonal variation of vitamin
D levels has been reported [2,8]. Studies of healthy
subjects at the end of the winter report prevalence
rates of 32% to 48% [10,46]. Season of testing was
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This is likely explained by the lack of exposure to
sunlight even during summer months as 64.2% of
patients reported spending \30 minutes per day
outdoors. Sunscreen use was common, with 31.3%
of patients reporting wearing sunscreen at all times,
and 75% of patients who spent greater than 2 hours
outdoors per day wearing sunscreen at all times.
We investigated potential risk factors specific to
HSCT including type of transplant, donor source,
stem cell source, the presence ofGVHD, the indication
for transplant, steroid use, and calcineurin inhibitor
use. None of these factors was found to be a significant
risk factor for deficiency, which is likely because of the
homogeneity of the transplant population. Patients
with insufficient and deficient levels were further
from transplant than those with normal levels. The
reason for this is unclear, but may be because of the
almost universal use of parenteral nutrition replete
with vitamin D during the transplant admission.
Previous studies report increased rates of vitamin
D deficiency in African American patients when com-
pared to non–African American populations [3,47].
Race (Caucasian, African-American, Hispanic, Asian,
or mixed ethnicity) was not a predictor of vitamin D
deficiency in our study, which may be because of the
lack of ethnic diversity in the study population. Other
risk factors reported in healthy populations, but not
significant in this population included milk consump-
tion, sunscreen use, and daily sun exposure. Although
the lack of a significant impact of any of these factors
may be because of the relatively small sample size, an
additional explanation may be that underlying risk
for deficiency associated with HSCT mitigated the
risk factors present in healthy populations.
PTH plays multiple roles in bone metabolism in-
cluding activation of osteoblasts, stimulation of renal
productionof1,25-dihydroxyvitamin,Dandaugmenta-
tion of the renal tubular absorption of calcium [11,13].
In healthy individuals, there is an inverse relationship
between vitamin D and PTH levels. There was no
correlation between PTH and vitamin D levels in this
study, which is unique from studies of deficiency in
other populations [2]. The explanation for the lack of
correlation is not clear. Hypomagnesemia is a potential
contributor, as it is known toblunt the PTHresponse to
low vitamin D levels [48]. However, this likely played
a small role in this study as it is our institutional standard
to provide magnesium supplementation to patients
who receive calcineurin inhibitors, and the majority of
patients in this study were treated with calcineurin
inhibitors. Despite standardized supplementation, it is
common for patients to need additional bolus infusions
ofmagnesium.Anotherpotential contributor is intrinsic
parathyroid dysfunction. Bakker et al. [49] reported
35% parathyroid hormone disturbance in children
following allogeneic HSCT. PTH disturbances werenot found in a study of children following autologous
HSCT [50].
The repletion strategy used in this study was
adequate, and the majority of patients corrected to
a normal posttreatment value. However, 36.4% of
patients had insufficient or deficient levels following at-
tempted correction. These patients may have needed
a longer period of repletion, and weekly treatment for
8 weeks has been recommended in other studies
[11,36]. Repletion occurred in the outpatient setting,
and poor compliance with the weekly regimen may
have played a role in the lack of normalization for
some patients. We advocate repeat testing after
attempted repletion for all patients and suggest
nutritional consult and continued treatment for those
with continued suboptimal levels. If there is concern
for difficulty with compliance, then ergocalciferol
should be administered in the clinic.
These data must be interpreted in the context of
known limitations. The sample size is relatively small
and may have been of insufficient size to identify po-
tential risk factors. Furthermore, all subjects were
transplanted in the northeastern United States, and
the results may not be generalizable to those living in
other areas. We did not study vitamin D levels in
a non-HSCT control group. It is therefore possible
that the low vitamin D levels were because of factors
other than transplant. Finally, we did not investigate
the effect of suboptimal vitamin D levels on bone or
overall health. The implications of vitamin D defi-
ciency on the health of children and adolescents
following HSCT remains unknown.
In summary, vitamin D insufficiency and defi-
ciency are common following HSCT, and adolescents
appear to be at increased risk for suboptimal levels.We
need prospective multicenter trials to examine the
prevalence of deficiency in multiple settings and to in-
vestigate the effect of suboptimal vitamin D status.ACKNOWLEDGMENTS
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